ProQR Therapeutics NV
PRQR2.125USD
+0.045+2.16%
取引時間 （ET）15分遅れの株価
228.89M時価総額
損失額直近12ヶ月PER
詳細情報 ProQR Therapeutics NV 企業名
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
企業情報
企業コードPRQR
会社名ProQR Therapeutics NV
上場日Sep 18, 2014
最高経営責任者「CEO」Mr. Daniel Anton de Boer
従業員数166
証券種類Ordinary Share
決算期末Sep 18
本社所在地Zernikedreef 9
都市LEIDEN
証券取引所NASDAQ Capital Market Consolidated
国Netherlands
郵便番号2333 CK
電話番号31881667000
ウェブサイトhttps://www.proqr.com/
企業コードPRQR
上場日Sep 18, 2014
最高経営責任者「CEO」Mr. Daniel Anton de Boer
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
株主統計
株主統計
比率
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
種類
株主統計
比率
Hedge Fund
21.84%
Corporation
16.06%
Investment Advisor
11.42%
Family Office
10.93%
Investment Advisor/Hedge Fund
4.91%
Individual Investor
2.00%
Research Firm
1.72%
Bank and Trust
0.04%
Venture Capital
0.02%
Other
31.06%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
122
61.04M
58.02%
-5.87M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
2023Q1
180
47.05M
58.19%
-9.38M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Eli Lilly and Company
16.90M
16.06%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
11.50M
10.93%
+40.00K
+0.35%
May 23, 2025
Adage Capital Management, L.P.
8.10M
7.7%
-1.50M
-15.62%
Mar 31, 2025
Privium Fund Management BV
4.99M
4.74%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
3.28M
3.12%
+459.51K
+16.27%
Mar 31, 2025
Millennium Management LLC
2.07M
1.97%
-756.63K
-26.76%
Mar 31, 2025
Sio Capital Management, LLC
2.05M
1.95%
--
--
Mar 31, 2025
abrdn Inc.
1.85M
1.76%
+1.85M
--
Mar 31, 2025
UBS Financial Services, Inc.
1.78M
1.69%
-511.49K
-22.30%
Mar 31, 2025
Kynam Capital Management LP
1.75M
1.66%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
0%
Avantis International Small Cap Value ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
Avantis International Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
